Tandem Diabetes Care (TNDM) Net Cash Flow Growth (1y) (2014 - 2026)
Tandem Diabetes Care (TNDM) Net Cash Flow Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -562.77% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 2,827.78% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -395.56% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 168.38% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -103.49% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -114.85% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -215.59% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -54.17% |
| 10 | Tandem Diabetes Care | 1.56 Bn | 1.10 Bn | 144.78 Mn | -1,443.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,443.03% |
| Mar 31, 2026 | 751.43% |
| Dec 31, 2025 | -114.33% |
| Sep 30, 2025 | 1,051.86% |
| Jun 30, 2025 | 175.49% |
| Mar 31, 2025 | -2,680.52% |
| Dec 31, 2024 | 185.11% |
| Sep 30, 2024 | 104.69% |
| Jun 30, 2024 | -455.61% |
| Mar 31, 2024 | 101.18% |
| Dec 31, 2023 | -144.41% |
| Sep 30, 2023 | -659.42% |
| Jun 30, 2023 | -84.41% |
| Mar 31, 2023 | -300.90% |
| Dec 31, 2022 | 215.50% |
| Sep 30, 2022 | -34.70% |
| Jun 30, 2022 | 195.80% |
| Mar 31, 2022 | -14.02% |
| Dec 31, 2021 | -17.37% |
| Sep 30, 2021 | 114.78% |